Craig C. Parker
CEO, President & DirectorMr. Craig C. Parker, MBA, is Director of Synthekine, Inc. Mr. Parker serves as Chief Executive Officer and President since March 2018 and Director at Surrozen, Inc., since April 2018. He serves as Director at InduPro. He joined the Surrozen, Inc. in March 2018. He joined The Column Group in 2024 as a Venture Partner. He was Senior Vice President and Head of Corporate Development at Jazz Pharmaceuticals Public Limited Company since August, 2014 until March, 2018. Mr. Parker served as Executive Vice President of Corporate Development and Scientific Affairs at Geron Corporation from 2012 to 2014. He served as the Senior Vice President of Strategy & Corporate Development of Human Genome Sciences Inc. from August 8, 2011 to November 2012. Mr. Parker has been involved in the science and business of the biotechnology industry for more than 25 years. His specific responsibilities have included business development, finance, portfolio analysis and strategic planning. Mr. Parker has experience in the biotechnology and investment industries. Mr. Parker was the Co-Founder of Vega Therapeutics, Inc. and served as its Chief Executive Officer from 2009 to 2011. He served as the Chief Financial Officer at Proteolix Inc. until April 2009. From February 2009 to January 2010, he was Senior Vice President of Corporate Development and Finance at Proteolix, a clinical development stage biotechnology company developing novel oncology drug candidates. From 2007 to 2009, Mr. Parker served as the President of DCD BioConsulting LLC. He served as the Chief Financial Officer at Onyx Therapeutics, Inc. since April 2009 and served as its Head of Corporate Development. He served as a Managing Director and Head of Biotechnology Equity Research at Lehman Brothers Holdings, Inc. Mr. Parker served as an Equity Analyst at Barclays Capital, Research Division and JP Morgan Chase & Co, Research Division from 1994 to 1998. He served as Research Analyst at Lehman Brothers Holdings Inc., Research Division. Mr. Parker served as an Analyst of Lehman Brothers Holdings, Inc. He served as Managing Director and Head of Biotechnology Equity Research of Lehman Brothers since joining it in 2002 until 2007. He served as Investment Banking Professional at J.P. Morgan & Co. Inc. Mr. Parker's career also includes a Wall Street research analyst. He served as a Partner and Equity Analyst of Sprout Group from 2001 to 2002. From 1999 to 2001, Mr. Parker served as Senior Vice President and General Manager of the Specialty Therapeutics Franchise at Immunex Corporation and was also responsible for Business Development, Strategy and several development stage drug candidates. While at Immunex, Mr. Parker led a number of important business development alliances. He served as head of a division of Immunex Corporation business unit. He served for Securities Analyst covering the biotechnology industry. He served as a Vice President and Senior Biotechnology Analyst at Donaldson, Lufkin and Jenrette from 1998 to 1999 and as Vice President at J.P. Morgan Securities and as its Analyst from 1994 to 1998. He served as an Equity Analyst at Donaldson, Lufkin & Jenrette Securities Corp., Research Division. He was Investment Banking Professional at Credit Suisse (USA), Inc. and Credit Suisse, Inc. Mr. Parker was an Entrepreneur-in-Residence at U.S. Venture Partners since November 2012. His career included senior executive positions in finance, biotechnology equity research and venture capital at various companies including Credit Suisse. Mr. Parker served as the Senior Vice President of Corporate Development at Geron Corporation from December 2012 to February 11, 2014 and served as its Member of The Executive Management Team since December 7, 2012. He serves as a Member of the Science Advisory Board of Life Sciences Institute, University of Michigan and Chairs the Institute's Leadership Council. He served as an Independent Director of vTv Therapeutics Inc. from July 2015 to April 29, 2019. Mr. Parker served as a Director of Sprout Group, Picoliter and Xcyte. Mr. Parker served as a Director of Gryphon Therapeutics, Inc. He is a guest lecturer at the Haas School of Business at UC Berkeley, the Stephen M. Ross School of Business at the University of Michigan and the Schools of Medicine and Engineering at the University of Michigan. He is an executive at successful, innovative companies in the biotechnology industry ranging from start-ups to public companies. He serves as Board of Directors at Synthekine. Mr. Parker was a Wall Street Journal All Star. He was ranked one of the top biotechnology analysts in both the Institutional Investor and Greenwich Research Surveys of U.S. equity analysts. He did graduate work in Medicine and Cell Biology at the Georgetown University School of Medicine. He has received an M.B.A. from the University of Michigan Stephen M. Ross School of Business and AB degree in Biological Sciences from the University of Chicago.
Positions
- Company NameSurrozen, Inc.Stock CodeSRZNPositionCEO, President & DirectorColleagues
- DJDavid J. WoodhouseIndependent Chairman of the Board
- CWCharles WilliamsCOO & Corporate Secretary
- YLYang LiExecutive Vice President of Research
- KCK. Christopher GarciaCo-Founder & Member of Scientific Advisory Board
- RNRoeland NusseCo-Founder & Member of Scientific Advisory Board
- CKCalvin KuoCo-Founder & Member of Scientific Advisor
